JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Nov 2017 Results of pooled retrospective analysis assessing natalizumab-associated progressive multifocal leukoencephalopathy from four observational studies (STRATIFY-2, STRATA, TOP, and TYGRIS) published in the Lancet Neurology.
15 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
10 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by the ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com